Poly I:C-induced tumor cell apoptosis mediated by pattern-recognition receptors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 530-534

  Zhao, Xiangzhong ^a   Ai, Miao ^b   Guo, Yuqi ^a   Zhou, Xianbin ^a   Wang, Li ^a   Li, Xia ^a   Yao, Chengfang ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b Linyi Maternity and Child Health Hospital   (China)

Author keywords

MDA 5; Pattern recognition receptors; Poly I:C; RIG I; TLR3; Tumor cell apoptosis

Indexed keywords

CASPASE 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; JANUS KINASE; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN P53; RETINOIC ACID INDUCIBLE PROTEIN I; STAT PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1;

APOPTOSIS; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; ENZYME ACTIVATION; HUMAN; MELANOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; HUMANS; INTERFERON INDUCERS; POLY I-C; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 84868297666     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1226     Document Type: Review

References (57)

1. Matsumoto M, Seya T. TLR3: Interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008;60:805.
2. De Clercq E. In search of a selective therapy of viral infections. Antiviral Res 2010;85:19.
3. Seya T, et al. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003; 23:4369.
4. Jasani B, et al. Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009;27: 3401.
5. Jin B, et al. Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol 2010; 2010:690438.
6. Kato H, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101.
7. Vercammen E, et al. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev 2008;21:13.
8. Galli R, et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol 2010;184:6658.
9. Khvalevsky E, et al. TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100: 1301.
10. Weber A, et al. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 2010;17:942.
11. Yoneda K, et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: Differential signaling mechanisms of TLR3-induced NFkappaB activation and apoptosis. Int J Oncol 2008;33:929.
12. Paone A, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29:1334.
13. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009;119:2399.
14. Nomi N, et al. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010;24:225.
15. Friboulet L, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: Critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia 2008;10:1183.
16. Jiang Q, et al. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008;8:12.
17. TauraM, et al. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 2010;101: 1610.
18. Zhang Y, et al. TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther 2009;8:1826.
19. Salaun B, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894.
20. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3.
21. Yamamoto M, et al. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668.
22. Matsumoto M, et al. Toll-like receptor 3: A link between tolllike receptor, interferon and viruses. Microbiol Immunol 2004;48:147.
23. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010;11:373.
24. Matsumoto M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154.
25. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006;2006:re13.
26. Boo KH, Yang JS. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med J 2010; 51:9.
27. Fujita T, et al. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 2007;89:754.
28. Kato H, et al. Length-dependent recognition of doublestranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008;205:1601.
29. Kawai T, et al. IPS-1, an adaptor triggering RIG-I- And Mda5-mediated type I interferon induction. Nat Immunol 2005;6:981.
30. Kumar H, et al. Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med 2006;203:1795.
31. Salaun, B, et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13:4565.
32. Chin AI, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010; 70:2595.
33. Dufour F, et al. The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against poly(I:C)-induced apoptosis. J Virol 2011;17:8689.
34. Kang DC, et al. mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A 2002;99:637.
35. Kang DC, et al. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: A novel type I interferon-responsive apoptosis-inducing gene. Oncogene 2004;23:1789.
36. Su ZZ, et al. Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol 2007;213:502.
37. Peng S, et al. Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 2009; 100:529.
38. Kubler K, et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol 2011; 10: 3028.
39. Kubler K, et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010;70:5293.
40. McAllister CS, Samuel CE. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J Biol Chem 2009; 284:1644.
41. Lin L, et al. Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. Cell Death Differ 2006;13:1982.
42. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: Implications for human disease. Oncogene 2006;25:6831.
43. Chiron D, et al. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 2009;182:4471.
44. Gilmore TD. Multiple myeloma: Lusting for NF-kappaB. Cancer Cell 2007;12:95.
45. Barbalat R, et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009;10:1200.
46. McCartney S, et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009;206:2967.
47. Onomoto K, et al. Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr Top Microbiol Immunol 316;2007:193.
48. Herzer K, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009;69:855.
49. Munoz-Fontela, C, et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205:1929.
50. Takaoka A, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516.
51. Han KJ, et al. Mechanisms of the TRIF-induced interferonstimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem 2004;279:15652.
52. Handa P, et al. FLIP (Flice-like inhibitory protein) suppresses cytoplasmic double-stranded-RNA-induced apoptosis and NF-kappaB and IRF3-mediated signaling. Cell Commun Signal 2011;9:16.
53. Takahashi K, et al. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J Immunol 2006;176:4520.
54. Sun R, et al. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J Biol Chem 2010;286:15918.
55. Kovalcsik E, et al. Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activation. Cancer Immunol Immunother 2011;60:1609.
56. Pries R, et al. Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med 2008;21:209.
57. Paone A, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxiainducible factor 1 alpha. Neoplasia 2010;12:539.